Single User License
INR 134840
Site License
INR 269680
Corporate User License
INR 404520

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Seasonal Influenza-Pipeline Review, H1 2015

Seasonal Influenza-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Seasonal Influenza-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Seasonal Influenza-Pipeline Review, H1 2015', provides an overview of the Seasonal Influenza's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Seasonal Influenza, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Seasonal Influenza and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Seasonal Influenza

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Seasonal Influenza and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Seasonal Influenza products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Seasonal Influenza pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Seasonal Influenza

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Seasonal Influenza pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Seasonal Influenza Overview 9

Therapeutics Development 10

Pipeline Products for Seasonal Influenza-Overview 10

Pipeline Products for Seasonal Influenza-Comparative Analysis 11

Seasonal Influenza-Therapeutics under Development by Companies 12

Seasonal Influenza-Therapeutics under Investigation by Universities/Institutes 16

Seasonal Influenza-Pipeline Products Glance 17

Late Stage Products 17

Clinical Stage Products 18

Early Stage Products 19

Seasonal Influenza-Products under Development by Companies 20

Seasonal Influenza-Products under Investigation by Universities/Institutes 24

Seasonal Influenza-Companies Involved in Therapeutics Development 25

AIMM Therapeutics B.V. 25

AltraVax Inc. 26

AmVac AG 27

Baxter International Inc. 28

Big DNA Ltd. 29

BioDiem Ltd 30

Celltrion, Inc. 31

Cilian AG 32

Codagenix, Inc. 33

ContraFect Corporation 34

Crucell N.V. 35

Eurocine Vaccines AB 36

FluGen, Inc. 37

GlaxoSmithKline plc 38

Hemispherx Biopharma, Inc. 39

Inovio Pharmaceuticals, Inc. 40

Johnson & Johnson 41

Liquidia Technologies, Inc. 42

Medicago Inc. 43

Merck & Co., Inc. 44

Novartis AG 45

Novavax, Inc. 46

OPKO Health, Inc. 47

PeptiVir, Inc. 48

Protein Sciences Corporation 49

TechnoVax, Inc. 50

Theraclone Sciences, Inc. 51

Touchlight Genetics Ltd. 52

TSRL, Inc. 53

Vaxart, Inc. 54

Vaxine Pty Ltd 55

VaxInnate Corporation 56

Vivaldi Biosciences Inc. 57

Zydus Cadila Healthcare Limited 58

Seasonal Influenza-Therapeutics Assessment 59

Assessment by Monotherapy Products 59

Assessment by Combination Products 60

Assessment by Target 61

Assessment by Mechanism of Action 63

Assessment by Route of Administration 65

Assessment by Molecule Type 67

Drug Profiles 69

(influenza B virus + influenza A virus [H3N2] + influenza A virus [H1N1]) vaccine-Drug Profile 69

A-06-Drug Profile 70

Alferon LDO-Drug Profile 71

AMV-401-Drug Profile 72

BDNA-002-Drug Profile 73

Bispecific Monoclonal Antibody to Inhibit Hemagglutinin for Seasonal and Pandemic Influenza-Drug Profile 74

CF-404-Drug Profile 75

CiFlu-Drug Profile 76

CR-8020-Drug Profile 78

CTP-25-Drug Profile 80

CTP-27-Drug Profile 81

FluCell-Drug Profile 82

FVH-1-Drug Profile 83

IKT-041-Drug Profile 84

Influ-nRNA-Drug Profile 85

influenza (quadrivalent) vaccine-Drug Profile 86

influenza (split virion, trivalent) vaccine-Drug Profile 88

influenza (trivalent) vaccine-Drug Profile 89

influenza (trivalent) vaccine-Drug Profile 90

influenza (trivalent) vaccine-Drug Profile 91

influenza [A/Christchurch/16/2010 (H1N1) + A/Texas/50/2012 (H3N2) + B/Massachusetts/02/2012 + B/Brisbane/60/2008] (split virion) vaccine-Drug Profile 92

influenza [H1N1] (quadrivalent) virus like particle vaccine-Drug Profile 94

influenza [strain A/H1N1] + [strain A/H3N2] + [strain B] (split virion) vaccine-Drug Profile 96

influenza [strain H1N1] (monovalent) vaccine-Drug Profile 98

influenza vaccine-Drug Profile 100

influenza vaccine-Drug Profile 101

influenza vaccine-Drug Profile 102

influenza vaccine-Drug Profile 104

INO-3510-Drug Profile 105

LIQ-001-Drug Profile 106

Monoclonal Antibodies to Inhibit Hemagglutinin for Seasonal Influenza and Pandemic Influenza-Drug Profile 107

NB-1008-Drug Profile 108

PVI-1000-Drug Profile 109

respiratory syncytical virus + influenza vaccine-Drug Profile 110

seasonal influenza (quadrivalent) vaccine-Drug Profile 111

seasonal influenza (trivalent) vaccine-Drug Profile 112

seasonal influenza (trivalent) vaccine-Drug Profile 115

seasonal influenza [A/H1N1, A/H3N2, B/Yamagata, B/Victoria] (quadrivalent) vaccine-Drug Profile 116

seasonal influenza [B/Yamagata] (monovalent) vaccine-Drug Profile 117

seasonal influenza [H3N2] vaccine-Drug Profile 118

seasonal influenza B vaccine-Drug Profile 119

seasonal influenza vaccine-Drug Profile 120

seasonal influenza vaccine-Drug Profile 121

seasonal influenza vaccine-Drug Profile 122

seasonal influenza vaccine-Drug Profile 123

Small Molecules for Influenza-Drug Profile 124

Small Molecules to Activate Sirtuin for Influenza-Drug Profile 125

TAK-850-Drug Profile 126

TCN-032-Drug Profile 127

TSR-026-Drug Profile 129

TSR-462-Drug Profile 130

TVX-001-Drug Profile 131

VAX-2012Q-Drug Profile 132

VB126 LAIV-Drug Profile 133

VH-244-Drug Profile 134

VX-787-Drug Profile 136

VXAA-1.1-Drug Profile 137

Seasonal Influenza-Recent Pipeline Updates 138

Seasonal Influenza-Dormant Projects 153

Seasonal Influenza-Discontinued Products 155

Seasonal Influenza-Product Development Milestones 156

Featured News & Press Releases 156

Appendix 162

Methodology 162

Coverage 162

Secondary Research 162

Primary Research 162

Expert Panel Validation 162

Contact Us 162

Disclaimer 163

List of Tables

Number of Products under Development for Seasonal Influenza, H1 2015 14

Number of Products under Development for Seasonal Influenza-Comparative Analysis, H1 2015 15

Number of Products under Development by Companies, H1 2015 17

Number of Products under Development by Companies, H1 2015 (Contd..1) 18

Number of Products under Development by Companies, H1 2015 (Contd..2) 19

Number of Products under Investigation by Universities/Institutes, H1 2015 20

Comparative Analysis by Late Stage Development, H1 2015 21

Comparative Analysis by Clinical Stage Development, H1 2015 22

Comparative Analysis by Early Stage Development, H1 2015 23

Products under Development by Companies, H1 2015 24

Products under Development by Companies, H1 2015 (Contd..1) 25

Products under Development by Companies, H1 2015 (Contd..2) 26

Products under Development by Companies, H1 2015 (Contd..3) 27

Products under Investigation by Universities/Institutes, H1 2015 28

Seasonal Influenza-Pipeline by AIMM Therapeutics B.V., H1 2015 29

Seasonal Influenza-Pipeline by AltraVax Inc., H1 2015 30

Seasonal Influenza-Pipeline by AmVac AG, H1 2015 31

Seasonal Influenza-Pipeline by Baxter International Inc., H1 2015 32

Seasonal Influenza-Pipeline by Big DNA Ltd., H1 2015 33

Seasonal Influenza-Pipeline by BioDiem Ltd, H1 2015 34

Seasonal Influenza-Pipeline by Celltrion, Inc., H1 2015 35

Seasonal Influenza-Pipeline by Cilian AG, H1 2015 36

Seasonal Influenza-Pipeline by Codagenix, Inc., H1 2015 37

Seasonal Influenza-Pipeline by ContraFect Corporation, H1 2015 38

Seasonal Influenza-Pipeline by Crucell N.V., H1 2015 39

Seasonal Influenza-Pipeline by Eurocine Vaccines AB, H1 2015 40

Seasonal Influenza-Pipeline by FluGen, Inc., H1 2015 41

Seasonal Influenza-Pipeline by GlaxoSmithKline plc, H1 2015 42

Seasonal Influenza-Pipeline by Hemispherx Biopharma, Inc., H1 2015 43

Seasonal Influenza-Pipeline by Inovio Pharmaceuticals, Inc., H1 2015 44

Seasonal Influenza-Pipeline by Johnson & Johnson, H1 2015 45

Seasonal Influenza-Pipeline by Liquidia Technologies, Inc., H1 2015 46

Seasonal Influenza-Pipeline by Medicago Inc., H1 2015 47

Seasonal Influenza-Pipeline by Merck & Co., Inc., H1 2015 48

Seasonal Influenza-Pipeline by Novartis AG, H1 2015 49

Seasonal Influenza-Pipeline by Novavax, Inc., H1 2015 50

Seasonal Influenza-Pipeline by OPKO Health, Inc., H1 2015 51

Seasonal Influenza-Pipeline by PeptiVir, Inc., H1 2015 52

Seasonal Influenza-Pipeline by Protein Sciences Corporation, H1 2015 53

Seasonal Influenza-Pipeline by TechnoVax, Inc., H1 2015 54

Seasonal Influenza-Pipeline by Theraclone Sciences, Inc., H1 2015 55

Seasonal Influenza-Pipeline by Touchlight Genetics Ltd., H1 2015 56

Seasonal Influenza-Pipeline by TSRL, Inc., H1 2015 57

Seasonal Influenza-Pipeline by Vaxart, Inc., H1 2015 58

Seasonal Influenza-Pipeline by Vaxine Pty Ltd, H1 2015 59

Seasonal Influenza-Pipeline by VaxInnate Corporation, H1 2015 60

Seasonal Influenza-Pipeline by Vivaldi Biosciences Inc., H1 2015 61

Seasonal Influenza-Pipeline by Zydus Cadila Healthcare Limited, H1 2015 62

Assessment by Monotherapy Products, H1 2015 63

Assessment by Combination Products, H1 2015 64

Number of Products by Stage and Target, H1 2015 66

Number of Products by Stage and Mechanism of Action, H1 2015 68

Number of Products by Stage and Route of Administration, H1 2015 70

Number of Products by Stage and Molecule Type, H1 2015 72

Seasonal Influenza Therapeutics-Recent Pipeline Updates, H1 2015 142

Seasonal Influenza-Dormant Projects, H1 2015 157

Seasonal Influenza-Dormant Projects (Contd..1), H1 2015 158

Seasonal Influenza-Discontinued Products, H1 2015 159

List of Figures

Number of Products under Development for Seasonal Influenza, H1 2015 14

Number of Products under Development for Seasonal Influenza-Comparative Analysis, H1 2015 15

Number of Products under Development by Companies, H1 2015 16

Comparative Analysis by Late Stage Development, H1 2015 21

Comparative Analysis by Clinical Stage Development, H1 2015 22

Comparative Analysis by Early Stage Products, H1 2015 23

Assessment by Monotherapy Products, H1 2015 63

Assessment by Combination Products, H1 2015 64

Number of Products by Top 10 Targets, H1 2015 65

Number of Products by Stage and Top 10 Targets, H1 2015 66

Number of Products by Top 10 Mechanism of Actions, H1 2015 67

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 68

Number of Products by Top 10 Routes of Administration, H1 2015 69

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 70

Number of Products by Top 10 Molecule Types, H1 2015 71

Number of Products by Stage and Top 10 Molecule Types, H1 2015 72

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AIMM Therapeutics B.V.

AltraVax Inc.

AmVac AG

Baxter International Inc.

Big DNA Ltd.

BioDiem Ltd

Celltrion, Inc.

Cilian AG

Codagenix, Inc.

ContraFect Corporation

Crucell N.V.

Eurocine Vaccines AB

FluGen, Inc.

GlaxoSmithKline plc

Hemispherx Biopharma, Inc.

Inovio Pharmaceuticals, Inc.

Johnson & Johnson

Liquidia Technologies, Inc.

Medicago Inc.

Merck & Co., Inc.

Novartis AG

Novavax, Inc.

OPKO Health, Inc.

PeptiVir, Inc.

Protein Sciences Corporation

TechnoVax, Inc.

Theraclone Sciences, Inc.

Touchlight Genetics Ltd.

TSRL, Inc.

Vaxart, Inc.

Vaxine Pty Ltd

VaxInnate Corporation

Vivaldi Biosciences Inc.

Zydus Cadila Healthcare Limited

Seasonal Influenza Therapeutic Products under Development, Key Players in Seasonal Influenza Therapeutics, Seasonal Influenza Pipeline Overview, Seasonal Influenza Pipeline, Seasonal Influenza Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com